2nd Quarter - Report

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$3,600,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Market Access and Intellectual Property (no specific bill)

LobbyistCovered position, as disclosed
VICTORIA BLATTER —

Contacted: Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); White House Office; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); SENATE; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Executive Office of the President (EOP); Natl Economic Council (NEC)

Taxation/Internal Revenue Code TAX

International tax issues, including: Tax Reform Puerto Rico Tax Incentives

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
REBECCA MANDELL —
NANCY ELLEN MCCARTHY —
HELEN RHEE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); Treasury, Dept of; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Natl Economic Council (NEC); White House Office; Executive Office of the President (EOP)

Health Issues HCR

Biosimilars, no specific bill PDUFA, no specific bill Prescription drug value issues, no specific bill S. 469 Affordable and Safe Prescription Drug Importation Act H.R. 1245 Affordable and Safe Prescription Drug Importation Act S.Con.Res.3 A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018-2026 (importation, non-interference) H.R. 1628 American Health Care Act; repeal/replace ACA Health Resources and Services Administration (HRSA) policy regarding rebates on drugs used in the outpatient setting to help low-income/uninsured populations (340B), no specific bill

Contacted: Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Treasury, Dept of; SENATE; Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Natl Economic Council (NEC); Office of Management & Budget (OMB); White House Office

Bills named: S. 469 (115th), H.R. 1245 (115th), H.R. 1628 (115th), S.Con.Res. 3 (115th)

Medicare/Medicaid MMM

Medicare Part B (Average Sales Price) (Medicare Program Part B Drug Payment Model proposed rule) Medicare Part D rebates Coding and reimbursement for oncology drugs/biologics End Stage Renal Disease and issues related to dialysis

LobbyistCovered position, as disclosed
VICTORIA BLATTER —
L NICOLE CURRIE —
JESSE KERNS —
REBECCA MANDELL —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); White House Office; Treasury, Dept of; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); SENATE; Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); Office of Management & Budget (OMB); Natl Economic Council (NEC)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.